Ofev (nintedanib) is a drug used in the treatment of idiopathic pulmonary fibrosis (IPF). The anti-fibrotic therapy is made by the pharmaceutical company Boehringer Ingelheim and was approved by the FDA in October 2014 and by the European Commission in January 2015.
Ofev slows down the progression of IPF by blocking tyrosine kinase enzymes which contribute to collagen growth. Slowing collagen growth leads to less fibrosis in the lungs and a longer life expectancy. Ofev has also been found to reduce the risk of serious flare-ups in IPF patients.
The drug is in capsule form and the recommended dose is 150mg tablets taken twice a day, ideally with food or before eating. Patients who cannot tolerate 300mg a day may be prescribed a lower dose.
Common side effects associated with Ofev include nausea, diarrhea, stomach pain, appetite loss, weight loss, high blood pressure and increased liver enzymes. Ofev is not advised for patients who suffer from moderate or severe liver problems. Those who have mild liver problems may be prescribed a lower dose of the drug and have their liver enzymes monitored. Find out more about Ofev here.
Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.